PARP Inhibitors in Breast Cancer: Latest Evidence

PARP Inhibitors in Breast Cancer: Latest Evidence Purpose of Review Breast cancer treatment continues to inhibitors in breast cancers are encouraging in patients with evolve as targeted therapeutic strategies are developed for germline deleterious BRCA1/2 mutations, continued work is the various molecular subtypes of breast cancer. The PARP needed to elucidate their utility beyond the BRCA1/2-mutated inhibitors represent a novel targeted therapy for tumors with population as has been possible in ovarian cancer. defective homologous recombination DNA repair. These Additionally, defining the ideal population and setting for agents may become standard new treatment options for pa- combination treatment remains a challenge and has been lim- tients harboring BRCA1/2 mutations and show promise in ited by synergistic toxicities. BRCA1/2 wild-type patients with triple-negative breast can- cers, which are treated predominantly with traditional cytotox- . . Keywords PARP inhibitors Breast cancer treatment ic chemotherapy. This review will discuss the results of clin- . . Targeted therapeutic strategies BRCA1/2 mutations Breast ical trials of these agents in breast cancer as well as important cancer ongoing and anticipated trials. Recent Findings Recent reports support the use of olaparib monotherapy in BRCA1/2-mutated metastatic cancer. Results of PARP inhibitor combinations with chemotherapy Introduction have been mixed. The addition of veliparib failed to http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Breast Cancer Reports Springer Journals

PARP Inhibitors in Breast Cancer: Latest Evidence

Loading next page...
 
/lp/springer_journal/parp-inhibitors-in-breast-cancer-latest-evidence-w3LkKTu1hE
Publisher
Springer US
Copyright
Copyright © 2017 by Springer Science+Business Media, LLC
Subject
Medicine & Public Health; Oncology; Internal Medicine; Surgical Oncology
ISSN
1943-4588
eISSN
1943-4596
D.O.I.
10.1007/s12609-017-0251-x
Publisher site
See Article on Publisher Site

Abstract

Purpose of Review Breast cancer treatment continues to inhibitors in breast cancers are encouraging in patients with evolve as targeted therapeutic strategies are developed for germline deleterious BRCA1/2 mutations, continued work is the various molecular subtypes of breast cancer. The PARP needed to elucidate their utility beyond the BRCA1/2-mutated inhibitors represent a novel targeted therapy for tumors with population as has been possible in ovarian cancer. defective homologous recombination DNA repair. These Additionally, defining the ideal population and setting for agents may become standard new treatment options for pa- combination treatment remains a challenge and has been lim- tients harboring BRCA1/2 mutations and show promise in ited by synergistic toxicities. BRCA1/2 wild-type patients with triple-negative breast can- cers, which are treated predominantly with traditional cytotox- . . Keywords PARP inhibitors Breast cancer treatment ic chemotherapy. This review will discuss the results of clin- . . Targeted therapeutic strategies BRCA1/2 mutations Breast ical trials of these agents in breast cancer as well as important cancer ongoing and anticipated trials. Recent Findings Recent reports support the use of olaparib monotherapy in BRCA1/2-mutated metastatic cancer. Results of PARP inhibitor combinations with chemotherapy Introduction have been mixed. The addition of veliparib failed to

Journal

Current Breast Cancer ReportsSpringer Journals

Published: Jul 28, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off